Zydus Cadila gets permission from DCGI for phase-1 clinical trial of novel molecule ZYIL1

Drug firm Zydus Cadila on Monday said it has received permission from Drugs Controller General of India (DCGI) to initiate phase-1 clinical trial of its novel molecule ZYIL1, indicated for use as an inhibitor for inflammation condition 'NLRP3'.

source https://timesofindia.indiatimes.com/india/zydus-cadila-gets-permission-from-dcgi-for-phase-1-clinical-trial-of-novel-molecule-zyil1/articleshow/79603851.cms